Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial

OBJECTIVE: In the phase 3 CELESTIAL trial, cabozantinib improved overall survival (OS) and progression-free survival (PFS) compared with placebo in patients with previously treated advanced hepatocellular carcinoma (HCC). This subgroup analysis evaluated cabozantinib in patients who had received sor...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelley, Robin Kate, Ryoo, Baek-Yeol, Merle, Philippe, Park, Joong-Won, Bolondi, Luigi, Chan, Stephen L, Lim, Ho Yeong, Baron, Ari D, Parnis, Francis, Knox, Jennifer, Cattan, Stéphane, Yau, Thomas, Lougheed, Julie C, Milwee, Steven, El-Khoueiry, Anthony B, Cheng, Ann-Lii, Meyer, Tim, Abou-Alfa, Ghassan K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451459/
https://www.ncbi.nlm.nih.gov/pubmed/32847838
http://dx.doi.org/10.1136/esmoopen-2020-000714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451459/
https://www.ncbi.nlm.nih.gov/pubmed/32847838
http://dx.doi.org/10.1136/esmoopen-2020-000714

Ejemplares similares